Sanofi and MyoKardia ended their heart drug partnership

ended a four-year partnership between Sanofi and MyoKardia to develop small molecule therapies for genetic mutations associated with certain heart diseases.By the end of the deal in April, MyoKardia will regain full rights to its drug program, including the experimental drugs mavacamten and MYK-491.The move is said to have nothing to do with any problems with the company's clinical data, but rather MyoKardia's hesitation about expanding the Sanofi deal. Sanofi therefore notified MyoKardia of its plans to terminate the agreement.The news comes as MyoKardia prepares to reveal its most important data within the next 24 months; The results of the Phase III Explorer study showed that mavacamten in hypertrophomyopathy is a genetic defect that causes thickening of heart tissue, irregular heartbeats, and potentially sudden and fatal strokes in young people. The results are expected to be completed in the second half of 2020.Over the past four years, MyoKardia has received about $230 million from Sanofi and notes the importance of maintaining 100 percent of its U.S. business rights in the U.S. during the break-up before the end of the research period. In the management of human capital, as well as the expansion of the additional rights of adaptive disorders, the relationship eventually died out.Tassos Gianakakos, chief executive of MyoKardia, commented: "As we prepare for and obtain evidence of the potential registration of mavacamten in obstructive hypertrophobic cardiomyopathy (HCM), regaining global rights allows us to capture the full value of the data generated over the next 12-24 months." The CONCEPT of MYK-491 for patients with dilational cardiomyopathy. MyoKardiaabout 7 percent, according to news reports. (Compiled by this web)